Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine treatment represent the standard of care for advanced hormone receptor (HR) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (1). Here, NR4A1 is linked to breast carcinoma.